Trial Profile

Phase II Study to Evaluate the Performance of PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Clinically Significant Prostate Cancer in Men Presenting Following a Positive Screen for Prostate Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 24 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gadobenic acid (Primary) ; Gadobutrol (Primary) ; Piflufolastat F18 (Primary)
Indications Prostate cancer
Focus Therapeutic Use

21 Oct 2025 Status changed from not yet recruiting to withdrawn prior to enrolment.
02 Aug 2022 Planned initiation date changed from 17 Jun 2022 to 17 Jun 2023.
04 Apr 2022 Planned initiation date changed from 17 Jun 2021 to 17 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com